INNATE PHARMA SA ADR
WKN: A2PSSH | ISIN: US45781K2042 | Ticker-Symbol: IDDASiehe auch INNATE PHARMA SA
Stuttgart
24.04.26 | 15:33
1,060 Euro
0,00 % 0,000
1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 1,160 | 1,210 | 25.04. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | Innate Pharma SA - 6-K, Report of foreign issuer | - | SEC Filings | ||
| INNATE PHARMA SA ADR Aktie jetzt für 0€ handeln | |||||
| Do | Innate Pharma SA: Innate Pharma to Participate in the D. Boral Capital Global Conference | 224 | Business Wire | Regulatory News:
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company"), a clinical-stage biotechnology company developing immunotherapies for cancer patients, today announced... ► Artikel lesen | |
| 17.04. | Innate Pharma legt Zwischenergebnisse zu Lungenkrebsstudie vor | 1 | Investing.com Deutsch | ||
| 17.04. | Innate Pharma reports interim lung cancer trial results | 1 | Investing.com | ||
| 17.04. | Innate Pharma SA: Innate Pharma to Present MATISSE Phase 2 Interim Results of IPH5201 in Clinical Trials Plenary Session at AACR 2026 | 413 | Business Wire | Encouraging early results catalyze continued investigation in the MATISSE Phase 2 study evaluating IPH5201, a first-in-class anti-CD39 monoclonal antibody, in combination with durvalumab and... ► Artikel lesen | |
| 13.04. | Innate Pharma SA - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 13.04. | Innate Pharma SA: Number of Shares and Voting Rights of Innate Pharma as of April 9, 2026 | 302 | Business Wire | Regulatory News:
Pursuant to the article L. 233-8 II of the French "Code de Commerce" and the article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or "AMF") General... ► Artikel lesen | |
| 13.04. | Innate Pharma SA: Innate Pharma to Hold Its Annual General Meeting of Shareholders on May 21, 2026 | 306 | Business Wire | Regulatory News:
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") will hold its Annual General Meeting of shareholders ("AGM") at 10:30 a.m. CEST on May 21, 2026... ► Artikel lesen | |
| 08.04. | Innate Pharma SA: Innate Pharma to Present at the AACR 2026 Oncology Industry Partnering Event | 329 | Business Wire | Regulatory News:
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company"), announced today that Yannis Morel, Chief Operating Officer, will present at the AACR Oncology... ► Artikel lesen | |
| 03.04. | Innate Pharma SA: Innate Pharma to Participate in the Kempen Life Sciences Conference | 503 | Business Wire | Regulatory News:
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company"), a clinical-stage biotechnology company developing immunotherapies for cancer patients, today announced... ► Artikel lesen | |
| 02.04. | Innate Pharma SA - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 02.04. | Innate Pharma SA: Innate Pharma Files Its 2025 Universal Registration Document (Document D'enregistrement Universel) and 2025 Form 20-f Annual Report | 319 | Business Wire | Regulatory News:
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") today announced the filing of its 2025 Universal Registration Document (Document d'enregistrement... ► Artikel lesen | |
| 01.04. | Innate Pharma SA - 20-F, Annual and transition report of foreign private issuers | - | SEC Filings | ||
| 26.03. | Innate Pharma Q4 2025: Strategischer Fokus und Kostendisziplin prägen Earnings Call | 4 | Investing.com Deutsch | ||
| 26.03. | Innate Pharma SA - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 26.03. | Innate Pharma GAAP EPS of -€0.55, revenue of €9.01M | 1 | Seeking Alpha | ||
| 26.03. | Innate Pharma SA: Innate Pharma Reports Full Year 2025 Financial Results and Business Update | 891 | Business Wire | Lacutamab TELLOMAK-3 confirmatory Phase 3 trial in cutaneous T-cell lymphoma (CTCL) is planned for initiation in H2 2026, subject to non-dilutive financing options currently under negotiation... ► Artikel lesen | |
| 19.03. | Innate Pharma SA - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 19.03. | Innate Pharma SA: Innate Pharma Announces Conference Call and Webcast for Full Year 2025 Financial Results | 411 | Business Wire | Regulatory News:
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company"), today announces that the Company will hold a conference call on Thursday, March 26, 2026 at 2... ► Artikel lesen | |
| 11.03. | Innate Pharma stock initiated with buy rating at BTIG on oncology pipeline | 3 | Investing.com |
1 2 3 4 Weiter >>
61 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| VALNEVA | 2,326 | -0,60 % | Valneva vor kritischer Marke: Droht jetzt der nächste große Absturz? - Was sich am Wochenende verändert hat | ||
| NOVAVAX | 6,960 | -0,85 % | Novavax (NVAX) Dips More Than Broader Market: What You Should Know | ||
| OCUGEN | 1,414 | -0,56 % | OCGN Gene Therapy Pipeline: Key 2026-27 Catalysts Ahead | ||
| INFLARX | 1,271 | +0,32 % | SCHOCKMELDUNG bei InflaRx NV: Warum Sie jetzt genau hinschauen sollten - Die Chance die sich zum Wochenstart ergibt! | ||
| INTELLIA THERAPEUTICS | 11,660 | +0,17 % | Intellia to report Phase 3 CRISPR gene editing trial results Monday | ||
| EDITAS MEDICINE | 2,470 | -0,40 % | Editas Medicine, Inc.: Editas Medicine Announces U.S. Patent and Trademark Office Reaffirms its Prior Decision in Favor of the Broad Institute in CRISPR/Cas9 Interference | CAMBRIDGE, Mass., March 27, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today... ► Artikel lesen | |
| VIVORYON THERAPEUTICS | 1,325 | +0,76 % | Vivoryon Therapeutics N.V. Reports Full Year 2025 Financial Results and Provides Business Update | Vivoryon Therapeutics N.V. Reports Full Year 2025 Financial Results and Provides Business Update
Compelling kidney function data and meta-analysis from two Phase 2 studies with varoglutamstat presented... ► Artikel lesen | |
| BIOCRYST PHARMACEUTICALS | 7,620 | -0,18 % | BioCryst Pharmaceuticals, Inc.: BioCryst Appoints Sandeep M. Menon Chief Research and Development Officer | - Experienced R&D leader with a track record of advancing innovative therapies from early development to global approval - RESEARCH TRIANGLE PARK, N.C., April 06, 2026 (GLOBE NEWSWIRE) -- BioCryst... ► Artikel lesen | |
| SAREPTA THERAPEUTICS | 17,280 | -0,23 % | Mesoblast: Neue Fantasie durch Technologie - und ein wachsender Zielmarkt | ||
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,331 | -0,37 % | PacBio and Lucid Genomics Announce Compatibility Collaboration to Advance Tertiary Analysis for Long-Read Sequencing | MENLO PARK, Calif. & BERLIN, April 21, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a premier developer of sequencing solutions, and Lucid Genomics GmbH, a provider of cutting-edge bioinformatics... ► Artikel lesen | |
| CARDIOL THERAPEUTICS | 1,200 | +0,67 % | Fixing Heart Disease Tied to Sudden Death in Young People | David Elsley - Cardiol Therapeutics | ||
| GERON | 1,337 | +4,05 % | Geron Corporation (GERN) Appoints Timothy Williams as EVP, Chief Legal Officer | ||
| ARBUTUS BIOPHARMA | 3,570 | -0,28 % | Arbutus Biopharma Corporation: Arbutus Receives U.S. FDA Fast Track Designation for Imdusiran for the Treatment of Chronic Hepatitis B | Fast Track designation has the potential to facilitate development and accelerate FDA review of imdusiran WARMINSTER, Pa., April 15, 2026 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:... ► Artikel lesen | |
| IMMUNITYBIO | 6,360 | 0,00 % | ImmunityBio startet Vertrieb von Krebsmedikament Anktiva in Saudi Arabien | ||
| MICROBOT MEDICAL | 1,900 | +1,06 % | Microbot Medical Inc.: Microbot Medical Welcomes Updated Occupational Protection Guidelines from Leading Medical Societies, Strengthening Commercial Position of LIBERTY |
Das Unternehmen INNATE PHARMA SA ADR kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 1,060 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu INNATE PHARMA SA ADR finden Sie auf Wallstreet Online.